한글목차

세계 에볼라 치료제 및 백신 시장의 미래는 병원 및 클리닉 시장과 외래수술센터(ASC) 시장에서 기회가 있으며, 유망할 것으로 예상됩니다. 세계 에볼라 치료제 및 백신 시장은 2025-2031년 28.6%의 연평균 복합 성장률(CAGR)로 2031년까지 약 2억 1,700만 달러에 달할 것으로 예상됩니다. 이 시장의 주요 촉진요인은 전염병의 확산, 에볼라 연구 및 에볼라 치료제 및 백신 개발에 대한 정부의 구상에 대한 지지를 받고 있다는 점입니다.

• Lucintel의 예측에 따르면 바이러스 유형별로는 자이르가 예측 기간 중 가장 높은 성장세를 보일 것으로 예상됩니다.
• 지역별로 보면 북미는 인수공통전염병의 확산, 첨단 의료기술의 도입이 진행되고 있고, 이 지역에는 잘 구축된 의료 인프라가 존재하므로 북미가 계속해서 가장 규모가 큰 지역이 될 것입니다.

에볼라 치료제 및 백신 시장에서의 전략적 성장 기회

에볼라 치료제 및 백신 시장은 특히 의약품 개발, 제조 및 유통 분야에서 여러 가지 성장 기회가 있습니다. 질병 발생시 보다 신속하고 효과적인 개입에 대한 수요가 시장 개발의 원동력이 되고 있습니다. 여기서는 용도별로 5가지 중요한 성장 기회를 소개하고자 한다:

• 확장되는 mRNA 백신 플랫폼: 에볼라 백신 개발에 사용되는 mRNA 기술은 주요 확장 분야로, COVID-19에 대한 mRNA 기술의 성공적인 사용은 에볼라 백신의 제조 및 보급에 적용될 수 있는 가능성을 넓히고, 발병시 대응에 획기적인 변화를 가져올 수 있습니다. 획기적인 변화를 가져올 수 있습니다.
• 고위험 지역에서의 백신 현지 생산: 서아프리카와 같이 에볼라 출혈열이 유행하기 쉬운 지역에서 백신 제조 시설에 투자하는 것은 대규모 성장을 가져올 수 있습니다. 현지 생산은 세계 공급망에 대한 의존도를 낮추고, 반응 시간을 단축하며, 지역의 준비 태세와 회복력을 향상시킬 수 있습니다.
• 다중 병원체 백신 개발: 에볼라 바이러스 감염증(EVD)을 포함한 여러 병원체를 방어할 수 있는 면역원을 설계하는 접근법도 확산되고 있습니다. 이를 통해 서로 다른 감염병을 대상으로 한 예방접종 활동의 연계성을 개선하여 보다 광범위한 예방이 효율적으로 이루어질 수 있습니다.
• 세계 보건 구상을 위한 협력: 정부, NGO, 제약회사가 협력하여 백신 연구개발 및 제공 체계를 전 세계에서 확대할 수 있습니다. 이러한 파트너십은 바이러스성 출혈열 환자를 치료하기 위한 혁신적인 항체 치료법에 필요한 자원을 모아 보다 쉽게 이용할 수 있도록 할 수 있습니다.
• 항체 치료의 발전: EVD의 치료 옵션으로서 단클론 항체 치료제는 아직 갈 길이 멀지만, 향후 개발 및 상업적 활용을 위한 매력적인 수단입니다. 항체 의약품은 고위험군에게 즉각적인 예방 효과를 제공하는 동시에 이미 감염된 사람들의 생존율을 높이고 백신 접종 캠페인을 보완할 수 있습니다.

이러한 전략적 성장 분야는 기술 혁신을 촉진하고, 제조 능력을 향상시키며, 전 세계로 진출하는 등 에볼라 치료제 및 백신 시장의 판도를 바꿀 수 있습니다. 그 결과, 다음번 에볼라 바이러스 유행에 보다 강력하고 효과적으로 대응할 수 있을 것으로 예상됩니다.

에볼라 치료제-백신 시장 활성화 요인 및 과제

에볼라 치료제 및 백신 시장의 발전과 성장에 영향을 미치는 몇 가지 시장 성장 촉진요인과 과제는 다음과 같습니다. 여기에는 기술적 진보, 경제적 측면, 규제적 고려사항 등이 포함됩니다. 이 시장에는 5가지 주요 촉진요인과 3가지 주요 과제가 있습니다.

에볼라 치료제 및 백신 시장을 주도하는 요인은 다음과 같습니다. :

• 백신 개발의 기술 혁명: mRNA 및 바이러스 벡터 플랫폼과 같은 백신 기술의 발전으로 보다 효율적이고 즉각적인 효과가 있는 에볼라 백신이 개발되고 있습니다. 이러한 개발은 에볼라 발병을 관리할 수 있는 세계 각국의 역량을 강화하는 데 필수적입니다.
• 정부 및 세계보건기구의 지원 증가: 각국 정부와 세계보건기구는 에볼라 연구와 백신 개발에 많은 투자를 하고 있습니다. 이러한 지원은 임상시험을 진행하고, 규제 당국의 승인을 받고, 백신을 널리 보급하는 데 필수적인 요소입니다.
• 예방 의료에 대한 수요 증가: 에볼라출혈열의 잠재적 영향에 대한 인식이 높아지면서 백신과 같은 예방책에 대한 수요가 증가하고 있습니다. 이러한 수요는 특히 에볼라 출혈열이 발생하기 쉬운 고위험 지역에서 시장을 주도하고 있습니다.
• 백신 생산 능력의 확대: 백신 시장의 중요한 촉진요인 중 하나는 전 세계, 특히 아프리카에서 백신 생산이 확대되고 있다는 점입니다. 현지 생산은 신속한 대응을 가능하게 하고, 외부 공급에 대한 의존도를 낮추어 향후 발병에 대한 대비를 용이하게 합니다.
• 공공-민간 파트너십과 협업: 공공 부문이 민간부문과 협력하면 에볼라 치료제 및 백신 시장에서 기술 혁신에 대한 접근성을 높일 수 있습니다. 이러한 협력 관계는 자원, 기술, 자금의 공동 활용을 통해 의약품 및 백신 개발 과정을 가속화할 수 있습니다.

에볼라 치료제 및 백신 시장이 해결해야 할 과제는 다음과 같습니다. :

• 규제 장애물 및 승인 지연: 복잡한 규제 상황을 헤쳐나가는 것은 어려운 일이며, 그 결과 에볼라에 대한 신약과 백신의 승인 및 유통이 지연될 수 있습니다. 결과적으로 이러한 지연은 발병시 국제적인 대응에 지장을 초래할 수 있습니다.
• 공급망 및 유통 문제: 인프라가 충분하지 않은 원격지로 의약품과 백신을 운송하는 것은 여전히 문제가 많습니다. 콜드체인 물류 및 운송 문제는 생명을 구하는 치료제에 대한 적시 접근을 방해할 수 있습니다.
• 백신 혐오와 대중의 인식: 백신 접종 확산은 잘못된 정보와 불신으로 인한 백신에 대한 주저로 인해 방해받고 있습니다. 성공적인 예방접종 캠페인을 위해서는 에볼라 백신에 대한 일반 대중의 인식과 수용을 개선해야 합니다.

에볼라 치료제 및 백신 시장에서 효과적인 치료제 개발 및 유통에 내재된 복잡성은 주요 촉진요인과 과제에서 잘 드러납니다. 기술 혁신과 세계 협력이 이러한 상황을 변화시키고 있지만, 이러한 혁신이 현실화되기 위해서는 규제와 물류의 장애물을 극복해야 합니다.

목차

제1장 개요

제2장 세계의 에볼라 출혈열 치료제·백신 시장 : 시장 역학

• 서론, 배경, 분류
• 공급망
• 업계의 촉진요인과 과제

제3장 시장 동향과 예측 분석(2019-2031년)

• 거시경제 동향(2019-2024년)과 예측(2025-2031년)
• 세계의 에볼라 출혈열 치료제·백신 시장 동향(2019-2024년)과 예측(2025-2031년)
• 세계의 에볼라 출혈열 치료제·백신 시장 : 신약 유형별
  • Zmapp
  • Favipiravir
  • Gs-5734
  • Tkm-Ebola
  • Avi-7537
• 세계의 에볼라 출혈열 치료제·백신 시장 : 백신 유형별
  • Cad3-Zebov
  • Rvsv-Zebov
  • 기타
• 세계의 에볼라 출혈열 치료제·백신 시장 : 바이러스주의 유형별
  • Zaire
  • Sudan
  • Tai Forest
  • Reston
  • Bundibugyo Virus
• 세계의 에볼라 출혈열 치료제·백신 시장 : 최종 용도별
  • 병원·클리닉
  • 외래 수술 센터
  • 기타

제4장 지역별 시장 동향과 예측 분석(2019-2031년)

• 세계의 에볼라 출혈열 치료제·백신 시장 : 지역별
• 북미의 에볼라 출혈열 치료제·백신 시장
• 유럽의 에볼라 출혈열 치료제·백신 시장
• 아시아태평양의 에볼라 출혈열 치료제·백신 시장
• 기타 지역의 에볼라 출혈열 치료제·백신 시장

제5장 경쟁 분석

• 제품 포트폴리오 분석
• 운영 통합
• Porter's Five Forces 분석

제6장 성장 기회와 전략 분석

• 성장 기회 분석
  • 세계의 에볼라 출혈열 치료제·백신 시장의 성장 기회 : 신약 유형별
  • 세계의 에볼라 출혈열 치료제·백신 시장의 성장 기회 : 백신 유형별
  • 세계의 에볼라 출혈열 치료제·백신 시장의 성장 기회 : 바이러스주의 유형별
  • 세계의 에볼라 출혈열 치료제·백신 시장의 성장 기회 : 최종 용도별
  • 세계의 에볼라 출혈열 치료제·백신 시장의 성장 기회 : 지역별
• 세계의 에볼라 출혈열 치료제·백신 시장의 새로운 동향
• 전략적 분석
  • 신제품 개발
  • 세계의 에볼라 출혈열 치료제·백신 시장의 생산능력 확대
  • 세계의 에볼라 출혈열 치료제·백신 시장에서의 기업인수합병(M&A), 합병사업
  • 인증과 라이선싱

제7장 주요 기업의 개요

• Arbutus Biopharma
• GlaxoSmithKline
• Johnson & Johnson Services
• Hemispherx Biopharma
• BioCryst Pharmaceuticals
• NanoViricides
• NewLink Genetics

영문목차

The future of the global Ebola drug and vaccine market looks promising with opportunities in the hospital & clinic and ambulatory surgical center markets. The global Ebola drug and vaccine market is expected to reach an estimated $217 million by 2031 with a CAGR of 28.6% from 2025 to 2031. The major drivers for this market are the growing prevalence of infectious diseases and supportive government initiatives toward Ebola research and the development of Ebola drugs and vaccines.

• Lucintel forecasts that, within the strain type category, zaire is expected to witness the highest growth over the forecast period.
• In terms of regions, North America will remain the largest region due to the growing prevalence of zoonotic diseases, the rising adoption of advanced medical technologies, and the presence of well-established healthcare infrastructure in the region.

Gain valuable insights for your business decisions with our comprehensive 150+ page report.

Emerging Trends in the Ebola Drug and Vaccine Market

The Ebola drug and vaccine market is a fast-changing environment where new technologies, partnerships, and regulatory frameworks are emerging to deal with the virus more effectively. These trends show a growing focus on global health security and innovation. Here are five key trends changing this market:

• Increased Emphasis on mRNA Vaccine Technology: The success of mRNA vaccines in COVID-19 has generated interest in using similar technology against Ebola. Companies are exploring mRNA platforms for faster and better vaccines. This could change how quickly new vaccines come to market during outbreaks.
• Scaling Up Global Vaccine Manufacturing Capacity: There is a strong move to expand vaccine manufacturing capacity globally, especially in Africa, to meet global demand. Local production minimizes dependence on imports and increases response time during outbreaks, improving preparedness and equitable distribution of the vaccine.
• Development of Therapeutic Antibodies: Monoclonal antibodies are being explored as an option for Ebola therapy, implying targeted treatment. This helps fill gaps left by vaccines by offering immediate protection and treatment options, particularly for those already infected or at high risk.
• Strengthening Global Health Partnerships: Public-private partnerships have become common, with government, non-governmental organizations, and pharmaceutical companies collaborating to drive innovation and access. These resources facilitate the mobilization of resources to hasten the development and dissemination of Ebola vaccinations and medications.
• Regulatory Harmonization and Fast-Track Approvals: Regulatory agencies are increasingly working together to harmonize standards and fast-track approvals for Ebola drugs and vaccines. Safe treatments reaching markets faster during emergencies enhance global health response efforts, making this an important trend.

These trends are thus collectively reshaping the Ebola drug and vaccine market, driving innovation, expanding access, and enhancing global preparedness. As they continue to evolve, these trends will likely result in more effective and equitable responses to managing Ebola outbreaks around the world.

Recent Developments in the Ebola Drug and Vaccine Market

The Ebola drug and vaccine market has experienced several significant developments aimed at ensuring global preparedness and response to the virus. These include new drug approvals and strategic alliances, among others. Here are five key developments that have major implications for the market:

• FDA Approval of Inmazeb: As the first-line treatment for Ebola, the FDA has approved Regeneron's Inmazeb, a combination of three monoclonal antibodies. The approval signifies an important milestone toward the provision of effective therapies for infected individuals, potentially lowering death tolls in subsequent outbreaks.
• WHO Prequalification of Johnson & Johnson's Zabdeno/Mvabea: The World Health Organization has prequalified Johnson & Johnson's two-shot Ebola vaccine regimen, known as Zabdeno/Mvabea, for emergency use. This move enhances global uptake of the vaccine, especially in areas with poor healthcare infrastructure, improving preventive measures against Ebola.
• Expansion of Manufacturing Facilities in Africa: Several pharmaceutical firms have announced intentions to establish vaccine manufacturing plants within Africa to increase local production during outbreaks, which will be much faster than relying on foreign suppliers when urgent distribution is needed.
• Strategic Collaboration Between GAVI and CEPI: The partnership between GAVI, The Vaccine Alliance, and the Coalition for Epidemic Preparedness Innovations (CEPI) has been strengthened to facilitate the development and equitable distribution of vaccines against Ebola disease. Therefore, this cooperation is essential for rapidly reaching at-risk populations through vaccination interventions.

By improving therapy options while expanding access and upgrading manufacturing capabilities, these developments are expected to have a significant impact on the Ebola drug and vaccine market. Combined, they create conditions for more effective global responses to future outbreaks of Ebola.

Strategic Growth Opportunities for Ebola Drug and Vaccine Market

The Ebola drug and vaccine market has several growth opportunities, particularly in the areas of drug development, manufacturing, and distribution. The demand for faster and more effective interventions during disease outbreaks drives these openings. Here are five significant opportunities for growth by application:

• Expanding mRNA Vaccine Platforms: mRNA technologies used to develop Ebola vaccines represent a major area of expansion. The successful use of mRNA technology during COVID-19 has opened up the possibility of its application in Ebola vaccine production and dissemination, which may be game-changing for responses during outbreaks.
• Locally Produced Vaccines in High-Risk Areas: Investing in vaccine production facilities within regions like West Africa that are prone to Ebola outbreaks can result in massive growth. Local manufacturing reduces reliance on global supply chains while hastening reaction times, thereby improving regional preparedness and resilience.
• Development of Multi-Pathogen Vaccines: One increasingly popular approach involves designing immunogens capable of protecting against multiple pathogens, including Ebola virus disease (EVD). This could improve coordination between immunization efforts targeted at different infectious diseases, offering broader protection with greater efficiency.
• Collaboration for Global Health Initiatives: Collaborations between governments, NGOs, and pharmaceutical companies can scale up vaccine R&D and delivery mechanisms worldwide. Such partnerships can pool the resources needed for innovative measures regarding therapeutic antibodies for treating patients with viral hemorrhagic fever, leading to greater accessibility.
• Progress in Therapeutic Antibody Treatment: Monoclonal antibody therapeutics as treatment options for EVD have a long way to go but still represent an attractive avenue for future developments and commercial exploitation. They can provide immediate protection to high-risk population groups while increasing survival rates among those already infected, complementing vaccination campaigns.

By fostering innovation, increasing manufacturing capabilities, and expanding global reach, these strategic growth areas could change the landscape of the Ebola drug and vaccine market. Consequently, they would likely lead to a much stronger and more effective response to the next outbreak of Ebola.

Ebola Drug and Vaccine Market Driver and Challenges

Several drivers and challenges influence the development and growth of the Ebola drug and vaccine market. These encompass technological advances, economic aspects, and regulatory considerations. There are five major drivers and three key challenges that affect this market.

The factors driving the Ebola drug and vaccine market include:

• Technological Revolution for Vaccine Development: Progress in vaccine technology, such as mRNA or viral vector platforms, has led to faster-acting Ebola vaccines that are more efficient. These developments are vital for enhancing global capacities to manage outbreaks.
• Increasing Government and Global Health Organization Support: Governments and global health organizations are investing heavily in Ebola research and vaccine development. This backing is fundamental for moving clinical trials forward, acquiring necessary approvals from regulators, and ensuring widespread distribution of vaccines.
• Rising Demand for Preventive Healthcare: The rising awareness of Ebola's potential impact has generated demand for preventive measures, such as vaccines. This demand drives the market, especially in high-risk areas where outbreaks of Ebola are more likely.
• Expansion of Vaccine Manufacturing Capabilities: One important driver in the market is the growth of vaccine manufacturing worldwide, particularly across Africa. Localized production provides quicker response times and reduces dependence on external supplies, making it easier to prepare for future outbreaks.
• Public-Private Partnerships and Collaborations: The public sector working jointly with the private sector facilitates access to innovation within the Ebola drug and vaccine market. These collaborations help pool resources, skills, and finances, thereby speeding up drug and vaccine development processes.

Challenges in the Ebola drug and vaccine market include:

• Regulatory Hurdles and Approval Delays: Navigating a complex regulatory landscape can be challenging, resulting in delays in the approval or distribution of new drugs or vaccines against Ebola. Consequently, these delays can hinder international responses to an outbreak.
• Supply Chain and Distribution Challenges: Transporting medicines and vaccines to remote areas lacking sufficient infrastructure remains problematic. Issues related to cold chain logistics and transportation can hinder timely access to life-saving treatments.
• Vaccine Hesitancy and Public Perception: Widespread immunization is impeded by vaccine hesitancy driven by misinformation and mistrust. To ensure successful vaccination campaigns, public perception and acceptance of Ebola vaccines must be addressed.

The complexities inherent in the development and distribution of effective treatments for the Ebola drug and vaccine market are illuminated by its major drivers and challenges. Although technological innovation and global collaboration have transformed this situation, it is necessary to overcome regulatory and logistical impediments for these breakthroughs to become reality.

List of Ebola Drug and Vaccine Companies

Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. With these strategies Ebola drug and vaccine companies cater increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base. Some of the Ebola drug and vaccine companies profiled in this report include-

• Arbutus Biopharma
• GlaxoSmithKline
• Johnson & Johnson Services
• Hemispherx Biopharma
• BioCryst Pharmaceuticals
• NanoViricides
• NewLink Genetics

Ebola Drug and Vaccine by Segment

The study includes a forecast for the global Ebola drug and vaccine market by novel drug type, vaccine type, strain type, end use, and region.

Ebola Drug and Vaccine Market by Novel Drug Type [Analysis by Value from 2019 to 2031]:

• Zmapp
• Favipiravir
• Gs-5734
• Tkm-Ebola
• Avi-7537

Ebola Drug and Vaccine Market by Vaccine Type [Analysis by Value from 2019 to 2031]:

• Cad3-Zebov
• Rvsv-Zebov
• Others

Ebola Drug and Vaccine Market by Strain Type [Analysis by Value from 2019 to 2031]:

• Zaire
• Sudan
• Tai Forest
• Reston
• Bundibugyo Virus

Ebola Drug and Vaccine Market by End Use [Analysis by Value from 2019 to 2031]:

• Hospitals & Clinics
• Ambulatory Surgical Centers
• Others

Ebola Drug and Vaccine Market by Region [Analysis by Value from 2019 to 2031]:

• North America
• Europe
• Asia Pacific
• The Rest of the World

Country Wise Outlook for the Ebola Drug and Vaccine Market

The Ebola drug and vaccine market has experienced significant advancements driven by global efforts to combat the deadly virus. With ongoing outbreaks and the potential for future epidemics, governments and pharmaceutical companies are intensifying their research and development efforts. This has led to accelerated approvals, increased funding, and the introduction of new therapies and vaccines. Key countries like the United States, China, Germany, India, and Japan are at the forefront of these developments.

• United States: The U.S. has been a leader in Ebola research, with recent developments including FDA approval for the Ervebo vaccine and deployment of monoclonal antibody treatments like Inmazeb. Moreover, the government continues to fund research for next-generation vaccines and therapeutics that will ensure preparedness for potential outbreaks while enhancing global health security.
• China: By partnering with African nations and international organizations, China has increased its focus on Ebola. Recent developments include approval of the Ad5-EBOV vaccine developed by CanSino Biologics, which is part of a broader strategy to enhance its influence in global health matters and support pandemic preparedness initiatives.
• Germany: As part of its commitment to the global healthcare industry, developmental efforts toward Ebola are ongoing. Recent developments involve collaborations with international organizations aimed at developing new vaccine candidates and treatments. Additionally, Germany is supporting African nations by funding them and providing technical assistance to strengthen their healthcare systems and response capacities.
• India: India is emerging as a major manufacturer of Ebola vaccines. Recent developments include Bharat Biotech's efforts to scale up production capabilities to manufacture these vaccines on a large scale. At the same time, the nation's pharmaceutical sector produces generic versions of Ebola treatments, making them more affordable for developing countries.
• Japan: Japan is focused on innovative ways to treat or prevent the spread of Ebola. Recent developments include the discovery of new antiviral drugs and the creation of rapid diagnostic tools. Finally, Japan's commitment to global health is demonstrated through its contributions to international research collaborations and funding for vaccine development.

Features of the Global Ebola Drug and Vaccine Market

Market Size Estimates: Ebola drug and vaccine market size estimation in terms of value ($M).

Trend and Forecast Analysis: Market trends (2019 to 2024) and forecast (2025 to 2031) by various segments and regions.

Segmentation Analysis: Ebola drug and vaccine market size by various segments, such as by novel drug type, vaccine type, strain type, end use, and region in terms of ($M).

Regional Analysis: Ebola drug and vaccine market breakdown by North America, Europe, Asia Pacific, and Rest of the World.

Growth Opportunities: Analysis of growth opportunities in different novel drug types, vaccine types, strain types, end uses, and regions for the Ebola drug and vaccine market.

Strategic Analysis: This includes M&A, new product development, and competitive landscape of the Ebola drug and vaccine market.

Analysis of competitive intensity of the industry based on Porter's Five Forces model.

If you are looking to expand your business in this or adjacent markets, then contact us. We have done hundreds of strategic consulting projects in market entry, opportunity screening, due diligence, supply chain analysis, M & A, and more.

This report answers following 11 key questions:

• Q.1. What are some of the most promising, high-growth opportunities for the Ebola drug and vaccine market by novel drug type (zmapp, favipiravir, gs-5734, tkm-Ebola, and avi-7537), vaccine type (cad3-zebov, rvsv-zebov, and others), strain type (zaire, sudan, tai forest, reston, and bundibugyo virus), end use (hospitals & clinics, ambulatory surgical centers, and others), and region (North America, Europe, Asia Pacific, and the Rest of the World)?
• Q.2. Which segments will grow at a faster pace and why?
• Q.3. Which region will grow at a faster pace and why?
• Q.4. What are the key factors affecting market dynamics? What are the key challenges and business risks in this market?
• Q.5. What are the business risks and competitive threats in this market?
• Q.6. What are the emerging trends in this market and the reasons behind them?
• Q.7. What are some of the changing demands of customers in the market?
• Q.8. What are the new developments in the market? Which companies are leading these developments?
• Q.9. Who are the major players in this market? What strategic initiatives are key players pursuing for business growth?
• Q.10. What are some of the competing products in this market and how big of a threat do they pose for loss of market share by material or product substitution?
• Q.11. What M&A activity has occurred in the last 5 years and what has its impact been on the industry?

Table of Contents

1. Executive Summary

2. Global Ebola Drug and Vaccine Market : Market Dynamics

• 2.1: Introduction, Background, and Classifications
• 2.2: Supply Chain
• 2.3: Industry Drivers and Challenges

3. Market Trends and Forecast Analysis from 2019 to 2031

• 3.1. Macroeconomic Trends (2019-2024) and Forecast (2025-2031)
• 3.2. Global Ebola Drug and Vaccine Market Trends (2019-2024) and Forecast (2025-2031)
• 3.3: Global Ebola Drug and Vaccine Market by Novel Drug Type
  • 3.3.1: Zmapp
  • 3.3.2: Favipiravir
  • 3.3.3: Gs-5734
  • 3.3.4: Tkm-Ebola
  • 3.3.5: Avi-7537
• 3.4: Global Ebola Drug and Vaccine Market by Vaccine Type
  • 3.4.1: Cad3-Zebov
  • 3.4.2: Rvsv-Zebov
  • 3.4.3: Others
• 3.5: Global Ebola Drug and Vaccine Market by Strain Type
  • 3.5.1: Zaire
  • 3.5.2: Sudan
  • 3.5.3: Tai Forest
  • 3.5.4: Reston
  • 3.5.5: Bundibugyo Virus
• 3.6: Global Ebola Drug and Vaccine Market by End Use
  • 3.6.1: Hospitals & Clinics
  • 3.6.2: Ambulatory Surgical Centers
  • 3.6.3: Others

4. Market Trends and Forecast Analysis by Region from 2019 to 2031

• 4.1: Global Ebola Drug and Vaccine Market by Region
• 4.2: North American Ebola Drug and Vaccine Market
  • 4.2.1: North American Market by Strain Type: Zaire, Sudan, Tai Forest, Reston, and Bundibugyo Virus
  • 4.2.2: North American Market by End Use: Hospitals & Clinics, Ambulatory Surgical Centers, and Others
• 4.3: European Ebola Drug and Vaccine Market
  • 4.3.1: European Market by Strain Type: Zaire, Sudan, Tai Forest, Reston, and Bundibugyo Virus
  • 4.3.2: European Market by End Use: Hospitals & Clinics, Ambulatory Surgical Centers, and Others
• 4.4: APAC Ebola Drug and Vaccine Market
  • 4.4.1: APAC Market by Strain Type: Zaire, Sudan, Tai Forest, Reston, and Bundibugyo Virus
  • 4.4.2: APAC Market by End Use: Hospitals & Clinics, Ambulatory Surgical Centers, and Others
• 4.5: ROW Ebola Drug and Vaccine Market
  • 4.5.1: ROW Market by Strain Type: Zaire, Sudan, Tai Forest, Reston, and Bundibugyo Virus
  • 4.5.2: ROW Market by End Use: Hospitals & Clinics, Ambulatory Surgical Centers, and Others

5. Competitor Analysis

• 5.1: Product Portfolio Analysis
• 5.2: Operational Integration
• 5.3: Porter's Five Forces Analysis

6. Growth Opportunities and Strategic Analysis

• 6.1: Growth Opportunity Analysis
  • 6.1.1: Growth Opportunities for the Global Ebola Drug and Vaccine Market by Novel Drug Type
  • 6.1.2: Growth Opportunities for the Global Ebola Drug and Vaccine Market by Vaccine Type
  • 6.1.3: Growth Opportunities for the Global Ebola Drug and Vaccine Market by Strain Type
  • 6.1.4: Growth Opportunities for the Global Ebola Drug and Vaccine Market by End Use
  • 6.1.5: Growth Opportunities for the Global Ebola Drug and Vaccine Market by Region
• 6.2: Emerging Trends in the Global Ebola Drug and Vaccine Market
• 6.3: Strategic Analysis
  • 6.3.1: New Product Development
  • 6.3.2: Capacity Expansion of the Global Ebola Drug and Vaccine Market
  • 6.3.3: Mergers, Acquisitions, and Joint Ventures in the Global Ebola Drug and Vaccine Market
  • 6.3.4: Certification and Licensing

7. Company Profiles of Leading Players

• 7.1: Arbutus Biopharma
• 7.2: GlaxoSmithKline
• 7.3: Johnson & Johnson Services
• 7.4: Hemispherx Biopharma
• 7.5: BioCryst Pharmaceuticals
• 7.6: NanoViricides
• 7.7: NewLink Genetics